Abstract Experimental evidence demonstrates that therapeutic temperature modulation with the use of mild induced hypothermia (MIH, defined as the maintenance of body temperature at 32-35°C) exerts significant neuroprotection and attenuates secondary cerebral insults after traumatic brain injury (TBI). In adult TBI patients, MIH has been used during the acute "early" phase as prophylactic neuroprotectant and in the sub-acute "late" phase to control brain edema. When used to control brain edema, MIH is effective in reducing elevated intracranial pressure (ICP), and is a valid therapy of refractory intracranial hypertension in TBI patients. Based on the available evidence, we recommend: applying standardized algorithms for the management of induced cooling; paying attention to limit potential side effects (shivering, infections, electrolyte disorders, arrhythmias, reduced cardiac output); and using controlled, slow (0.1-0.2°C/h) rewarming, to avoid rebound ICP. The optimal temperature target should be titrated to maintain ICP <20 mmHg and to avoid temperatures <35°C
Introduction
Management of traumatic brain injury (TBI) is aimed to attenuate the amount of so-called secondary brain injury (SBI), i.e. early pathological events (including intracranial hypertension, cerebral hypoxia/ischemia, energy dysfunction, non-convulsive seizures, and systemic insults) that might occur immediately after primary cerebral insult and may add further burden to patient outcome. In the absence of an effective strategy for early neuroprotection, emergent resuscitation and evacuation of surgical lesions, together with the implementation of standardized algorithms for the management of SBI, has considerably reduced mortality and has contributed to improve overall outcome and quality of care [1] [2] [3] [4] . Secondary elevations of intracranial pressure (ICP) are frequent in patients with severe TBI and constitute a major determinant of SBI and outcome. Recent studies and meta-analysis have shown increased utilization of ICP monitoring and effective control of elevated ICP burden to be associated with an improvement of outcome after TBI [5, 6] .
Mild induced hypothermia (MIH, i.e. the induction of therapeutic cooling to a body temperature of 32-35°C) has long been used as a non-pharmacological measure to control secondary elevations of ICP after TBI [3] , and may be a valid therapeutic option for refractory elevated ICP [7••] , provided adequate management of potential side effects that may occur during both the hypothermic and rewarming phases.
While MIH may have a place for the management of elevated ICP, its role as an early neuroprotectant is more controversial. A number of animal models have repeatedly demonstrated the benefit [8] . However, the translation of these positive data into clinical human studies has proven difficult, and the benefit of MIH as early neuroprotective strategy after TBI has not been clearly demonstrated, with conflicting data and several negative randomized controlled trials [9-26••] .
In this review, we will first discuss main neuroprotective properties of MIH and the potential beneficial effects of MIH in attenuating SBI after TBI. We will then review the role of MIH in the management of SBI in adult TBI patients, with a particular attention to the clinical utility of MIH to treat elevated refractory ICP. We will also review main clinical studies that tested MIH as early neuroprotectant after adult TBI, and conclude with a discussion of the potential optimal utilization of MIH and management of hypothermia-related side effects. Therapeutic temperature modulation for fever control (induced normothermia) will not be addressed.
Mechanisms by Which MIH Attenuates SBI
MIH attenuates secondary pathological insults following TBI. These pathological processes start minutes to hours after neurotrauma and may continue for up to 72 h or longer [27] . Therefore, it is important to realize that the therapeutic window of MIH is wide and very much depends on the specific therapeutic aim, and on the time interval between TBI and both the initiation and the duration of therapeutic cooling.
Hypothermic neuroprotection acts at several sites and might exert benefits at different time-points from TBI start (Fig. 1) .
Acute "Early" Phase (Minutes to Hours) Ischemia, Excitotoxicity, Energy Failure, and Cell Death Cascades Cerebral ischemia/hypoxia may occur early after TBI, due to direct parenchymal and vascular disruption, acute vasospasm, and post-traumatic vascular stretching and shearing. Nonischemic energy dysfunction, increased glucose utilization and cerebral hyperglycolysis are also frequent and may cause substrate depletion and energy crisis [28, 29] . Excitotoxicity describes the process by which glutamate and others excitatory amino acids cause neuronal damage [30] . Glutamate exposure produces activation of receptors that leads to calcium influx [30] . Increased intracellular calcium concentration activates several proteases, lipases, and endonucleases and increases nitric oxide and oxygen free radicals. This exacerbates mitochondrial damage and DNA alteration, and culminates in necrotic and apoptotic cell death [31] through caspase-independent and caspase-dependent pathways [32] .
Effect of MIH: MIH inhibits early molecular cascades involved in the exacerbation of secondary cerebral damage after TBI, particularly by altering the expression of immediate early genes and by suppressing early cellular stress responses [38] . f. Prevention of Apoptotic Death: MIH inhibits apoptosis by modulating gene expression and transcription of factors involved in neuronal apoptosis (e.g. reduction of proapoptotic BAX expression and increase of anti-apoptotic BCL-2 expression), and by inhibiting caspase-dependent and caspase-independent apoptotic pathways [8] .
Sub-Acute "Late" Phase (24 Hours to 7 Days)
Brain Edema and Swelling, Blood Brain Barrier Disruption
After TBI, brain swelling results from both vasogenic and cytotoxic edema [39, 40] . Vasogenic edema results from blood-brain barrier (BBB) disruption leading to an increase in extracellular volume. Furthermore, because of potential impairment of cerebrovascular reactivity, any elevation of mean arterial pressure might translate into increased cerebral blood volume and edema [41] . Cytototoxic or cellular edema may also play a major role [42] . Cellular edema may occur because of a) homeostatic uptake of excitatory amino acids, b) water movement through aquaporins, and c) ionic pump failure [43] [44] [45] .
Inflammation
Cytokines (TNF-α, interleukin-1β, eicosanoids, neutrophiles, and macrophages) all contribute to post-TBI inflammatory cascades and secondary cerebral damage and repair [46, 47] . Contusion and local tissue necrosis trigger neutrophil influx, increases in inducible nitric oxide synthase and macrophage infiltration [48] . Macrophage infiltration and the differentiation of endogenous microglia into resident macrophages may signal the link between inflammation and regeneration with elaboration of trophic factors (i.e., nerve growth factor, nitrosothiols, vascular endothelial growth factor) [49, 50] . Studies in animal models suggest early detrimental effects of a number of inflammatory mediators, but beneficial effects of inflammation on long-term outcome [46] .
Non-Convulsive Seizures
Severe TBI is associated with an increased risk of nonconvulsive, clinically subtle or silent seizures [51] . These seizures are associated with increased secondary cerebral damage and tissue loss [52, 53] .
Effect of MIH:
a. Reduction of BBB Disruption and Limitation of Brain Swelling: At a microcirculatory level, MIH has a major role in reducing BBB disruption by preserving vascular endothelial function and reducing extracellular protease expression [37••, 54-56] . MIH inhibits micro-thrombus formation induced by brain injury [57, 58] , the cascade of reactions induced by reperfusion [8, 57, 59] , and the permeability of cellular membranes, with consequent improvement in neuronal function and homeostasis [8, 57] . At a macrocirculatory level, MIH reduces cerebral blood flow and preserves cerebrovascular reactivity [7] , thereby minimizing cerebral blood volume and brain swelling. This might explain the effectiveness of MIH in reducing ICP after TBI [7, 60 ••] (see below). b. Inhibition of Inflammation: MIH decreases inflammatory cell infiltration, activation of immune transcription factors and elaboration of damaging free radicals such as superoxide, peroxinitrite, hydrogen peroxide, and hydroxyl radicals [61] [62] [63] [64] . c. Inhibition of Epileptic Activity and Seizures: MIH attenuates seizure activity [65, 66] .
Chronic Phase (Weeks to Months)
Post-Traumatic Axonal Injury
MIH might modulate the distribution and extension of axonal injury by enhancing neurogenesis [67, 68] , gliogenesis, and angiogenesis [68, 69] , and by promoting neural outgrowth, neuronal connectivity, and synapse formation [70] . Finally, abundant experimental evidence demonstrates that hypothermic neuroprotection translates into better tissue and neurological recovery (see ref. [37••, 71] for extensive review).
Clinical Utility of MIH
MIH has long been suggested as a therapeutic strategy after TBI [72] . Clinical trials evaluating MIH after TBI can be divided into two categories, according to the therapeutic aims:
1. Trials in which MIH was applied in the "late phase" of TBI, to control elevated ICP; 2. Studies in which MIH was applied in the "early phase"
of TBI, as prophylactic neuroprotectant.
"Late" MIH for the Management of Elevated ICP in Patients with TBI Intracranial hypertension-defined as the sustained elevation of ICP above 20-25 mmHg-is frequent in patients with severe TBI and an abnormal CT scan, and is associated with increased mortality and worse functional outcome [5, 6] . A stepwise approach for the treatment of intracranial hypertension is usually applied. So called first-step therapies consist of treating situations associated with increased cerebral blood volume (seizures, fever, agitation), sedation and neuromuscular blockade, intermittent CSF drainage if available, osmotic fluids (mannitol, hypertonic saline), and controlled moderate hyperventilation. If intracranial hypertension is refractory to these measures and the CT scan does not show surgical treatable lesions, additional so-called second-step therapies are applied. These consist of MIH, barbiturates or decompressive craniectomy.
Effect on ICP MIH was tested in severe TBI patients with refractory intracranial hypertension in 17 controlled trials with outcome data [9-26•] . Compared to normothermia, MIH was associated with significant reduction in elevated ICP in the majority of these studies (Table 1) . Furthermore, 12 of these 17 trials reported significant improvements in outcome associated with MIH-related reduction of ICP [9, 11, 13, 14, [17] [18] [19] [21] [22] [23] [24] [25] . The magnitude of the effect of MIH on ICP reduction was recently reported in a study by Schreckinger et al. in a non-systematic review [7••] . First, the authors analyzed 11 prospective randomized clinical trials that included a total of 367 patients and compared MIH versus normothermia to control elevated ICP after TBI. In all the studies analyzed, MIH was invariably associated with lower ICP than normothermia. In six additional studies, the effect of MIH on ICP reduction was examined: on average, the reduction in ICP obtained by MIH was 10 mmHg and the decrease varied from 5-23 mmHg. Across the studied analyzed, the effect of MIH on ICP reduction was superior to that achieved with moderate hyperventilation, barbiturates and mannitol [7••] .
In a recent systematic review by Sadaka et al., the effect of MIH on ICP reduction was further corroborated: among 16 studies comparing MIH to normothermia in TBI patients, all studies found significantly lower ICP in patients treated with MIH (range 10-25 mmHg) than in those assigned to normothermia (range 20-35 mmHg) [6] .
These studies suggest that MIH is an effective therapy for intracranial hypertension.
Optimal Target Temperature
The optimal target temperature of MIH when used for ICP control is not precisely defined. Tokutomi et al. suggest that decreasing body temperature to .5°C effectively treats intracranial hypertension, while maintaining sufficient cerebral perfusion pressure without cardiac dysfunction or oxygen debt [73] . Resting energy expenditure and cardiac output decreased progressively with hypothermia. Oxygen delivery and oxygen consumption decreased to abnormally low levels at rectal temperatures <35°C, and the correlation between them became less significant at <35°C than when temperatures were ≥35°C [73] . Gupta et al. showed MIH below 35°C decreases brain tissue oxygenation [74] . Thus, 35-35.5°C seems to be the optimal temperature at which to treat patients with intracranial hypertension following severe TBI. Instead of applying fixed temperature targets, we suggest that MIH is targeted on an individual basis, titrating temperature to maintain ICP below 20 mmHg. Temperatures < 35°C are associated with increased side effects, including cardiac, hemodynamic and infectious complications. 
Duration of induced hypothermia
The optimal duration of therapeutic MIH is not known. A meta-analysis by MacIntyre et al. suggested that duration of MIH >48 h was associated with better outcomes [75] . Jiang et al. compared "short-term" MIH (n0107 patients, treated for an average of 2 days) to "long-term" MIH (n0108 patients, treated on average for 5 days), and found long-term MIH significantly improved outcome in a group of severe TBI patients with cerebral contusions and intracranial hypertension, without significant complications [76] . Importantly, adverse effects of cooling have been observed principally in the initial phase of MIH, and duration of MIH has not been demonstrated to significantly increase the rate of pneumonia and other complications [15, 19] .
Rewarming
In experimental studies, posttraumatic MIH followed by slow rewarming provides maximal neurprotective effect, while rapid rewarming not only reverses the protective effects of MIH, but also aggravates post-traumatic induced cerebral damage [77, 78] . The use of uncontrolled rewarming may potentially offset the benefits of MIH, particularly because it may cause rebound intracranial hypertension [10, 11] . [80] . A recent study documented episodes of rebound intracranial hypertension during and early after the rewarming phase [26•] . Rapid rewarming was found to correlate with worse outcomes after TBI in a recent study [81] .
In conclusion, slow controlled (0.1-0.2°C/h) rewarming is recommended after MIH to reduce the risk of rebound cerebral edema and intracranial hypertension [76] .
Focal Versus Diffuse Injury
The type of TBI (contusion vs. diffuse injury) is also a relevant issue: MIH is particularly effective in reducing elevated ICP associated with post-TBI contusions, while patients with elevated ICP secondary to diffuse injury appear to respond less well to hypothermia [26••, 76] .
Based on the available data, the following can be recommended when applying MIH for the management of refractory elevated ICP: HypoT Hypothermia; ICH Intracranial Hypertension; NA Not Available; T temperature -The optimal target temperature should be titrated to maintain ICP below 20-25 mmHg, and to around 35°C ; temperatures <35°C may reduce cerebral perfusion pressure and oxygen delivery; -The optimal duration of MIH depends on the severity of intracranial hypertension; MIH should be individualized and may need to be continued for more than 48 h, and up to 4-5 days until the peak period of intracranial hypertension (3-5 days) subsides; -Withdrawal from MIH should be slow, using controlled rewarming (0.1-0.2°C/h); -Patients with refractory elevated ICP following focal TBI (mainly, post-traumatic hemorrhagic contusions) may respond better to MIH than those with diffuse injury.
In summary, MIH is effective in reducing elevated ICP, and is therefore a valid therapeutic option of intracranial hypertension after TBI. Eurotherm3235Trial, an international, multicentre, randomized controlled trial, will examine the effects of MIH at 32-35°C as a treatment for raised intracranial pressure after TBI. Subjects are allowed to be enrolled up to 72 h after TBI; the duration of cooling is titrated upon the time to control ICP effectively (between 2 and 5 days), and rewarming is used at a rate of 1°C per 4 h [82•].
"Early" MIH as Prophylactic Neuroprotectant in Patients with TBI Thirteen controlled single-center studies conducted on adult TBI patients demonstrated significantly better outcome associated with MIH [9, 11, 13, 14, [16] [17] [18] [19] [21] [22] [23] [24] [25] . In contrast, three multicenter randomized controlled trials that tested early (within 10 h after TBI) "short-term" (max. 48 h) MIH [15, 16, 26•] , found no benefit with regards to survival and neurological outcome. The largest trial included 392 patients (199 in the hypothermia group and 193 in the normothermia group) [15] . Outcome at 6 months after TBI was not significantly different in the two groups (relative risk of poor outcome 1, 95 % CI 0.8-1.2, p00.99). Internal validity of this trial was lowered by inter-center variability in the management of induced hypothermia, age of subjects, severity of illness scoring, and the management of cerebral perfusion pressures and hemodynamics [83] . Lesser expertise with the management of MIH was associated with more complications.
Given the discrepancy between single center and multicenter trials, many meta-analyses have attempted to further examine the impact of prophylactic MIH on outcome after TBI [76, [84] [85] [86] [87] [88] [89] [90] [91] [92] . Four of these metaanalyses have been published as Cochrane systematic When limiting the analysis to high quality RCT, i.e. to the nine studies with good allocation concealment, mortality and unfavorable outcome did not differ between the two groups. The efficacy of early MIH in reducing death and unfavorable outcome was only found in low quality trials, which overestimate the treatment effect [91•] . Data from recent meta-analyses on the effect of MIH used as early neuroprotectant are summarized in Fig. 2 .
Finally, Clifton et al. recently published the National Acute Brain Injury Study: Hypothermia II (NABIS: H II), a multicentre RCT including patients who were 16-45 years old after severe, non-penetrating TBI, treated with MIH [26•] . The trial was stopped after inclusion of 108 patients, and no effect on outcome was seen (relative risk of poor outcome of MIH vs. normothermia 1.08, 95 % CI 0.76-1.53; p00.67). Subgroup analysis found that patients with surgically evacuated hematomas treated with MIH had better outcome than those assigned to normothermia (p00.02), while those with diffuse brain injury treated with hypothermia had a trend to poorer outcome (p00.09). Although not conclusive, these data suggest different effects of MIH depending on the type of TBI. Moreover, one-third of surgically treated patients in the hypothermia group had decompressive craniectomies, which itself may have suppressed rebound intracranial hypertension [26•] . This again raises the difficulty of including heterogeneous patients with TBI in clinical trials [93] .
Management of Side Effects of MIH

Temperature-Related
Shivering MIH may cause shivering, which in turn might increase oxygen consumption and energy expenditure [94] , and reduce brain tissue oxygenation [95] . Recognition of shivering is mandatory and can be achieved by using ad hoc scales [96] . Therapies of shivering include increased sedation (propofol) and analgesia (fentanyl), meperidine, dexmedetomidine, buspirone [97] .
Infections MIH is associated with increased infections [60••, 98] . Careful surveillance of infections is mandatory, and includes regular microbiological sampling and followup of infection biomarkers such as procalcitonin. Infection prevention, like the use of selective digestive decontamination, may reduce the infection risk related to MIH [99] .
Cardiovascular MIH is associated with reduced heart rate and cardiac output, which are usually well tolerated. Arrhythmias are associated with hypokalemia, generally during the rewarming phase [60••] , and must be prevented by close monitoring of potassium levels.
Hemorrhage Despite prolonged partial thromboplastin time (PTT) and thrombocytopenia having been reported during MIH [60••] , no study has documented an increased risk of bleeding.
Technique-Related
Skin Injury Surface cooling devices have been associated with skin lesions.
Thrombosis Using intravascular devices for MIH may be associated with vascular (venous) thrombosis, particularly when MIH is maintained for more than 48-72 h [100] . When using prolonged surface cooling, we also recommend carefully monitoring patients for potential skin injuries.
Development of local standardized algorithms for the management of MIH is recommended, and may help reduce Fig. 2 Summary of recent meta-analyses that evaluated the effect of mild induced hypothermia versus normothermia on the outcome (mortality, in red and proportion with poor outcome, in blue) in adult severe TBI patients side effects of MIH and increase the potential benefit of the therapy [84] .
Conclusion
Therapeutic hypothermia has many neuroprotective effects that may all contribute to reduce secondary cerebral damage after traumatic brain injury. In clinical practice, therapeutic hypothermia has been used in the early phase of traumatic brain injury, as prophylactic neurprotectant, and in the late phase, to control brain edema and elevated intracranial pressure.
Mild induced hypothermia to 32-35°C is effective in reducing elevated intracranial pressure and is a valid therapeutic. Based on the available clinical evidence, we recommend the development and application of local standardized algorithms for the management of induced cooling. These should pay particular attention to limiting side effects (shivering, infections, electrolyte disorders, arrhythmias, reduced cardiac output) and to the use of controlled, slow (0.1-0.2°C/h) rewarming. The optimal temperature target should be titrated to maintain ICP below 20-25 mmHg and as much as possible to avoid body temperature <35°C. The duration of cooling should be individualized and may need to be maintained for longer than 48 h, until the resolution of brain edema and intracranial hypertension. Patients with refractory elevated ICP following focal TBI (hemorrhagic contusions) may respond better to mild induced hypothermia than those with diffuse injury. Randomized controlled trials that evaluate the impact on outcome of mild induced hypothermia in adult traumatic brain injury patients with elevated intracranial pressure are underway.
In contrast, based on the available evidence, we do not recommend the use of mild induced hypothermia as prophylactic neuroprotectant in the early phase of traumatic brain injury.
